Transgenic	O
expression	O
of	O
PML/RARalpha	B-protein
impairs	O
myelopoiesis	O
.	O

The	O
translocation	O
found	O
in	O
acute	O
promyelocytic	O
leukemia	O
rearranges	O
the	O
promyelocytic	B-DNA
leukemia	I-DNA
gene	I-DNA
(	O
PML	B-DNA
)	O
on	O
chromosome	B-DNA
15	I-DNA
with	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
(	O
RARalpha	B-protein
)	O
on	O
chromosome	B-DNA
17	I-DNA
.	O

This	O
yields	O
a	O
fusion	O
transcript	O
,	O
PML/RARalpha	B-protein
,	O
a	O
transcription	B-protein
factor	I-protein
with	O
reported	O
dominant	O
negative	O
functions	O
in	O
the	O
absence	O
of	O
hormone	O
.	O

Clinical	O
remissions	O
induced	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
treatment	O
in	O
acute	O
promyelocytic	O
leukemia	O
are	O
linked	O
to	O
PML/RARalpha	B-protein
expression	O
in	O
leukemic	B-cell_type
cells	I-cell_type
.	O

To	O
evaluate	O
the	O
PML/RARalpha	B-protein
role	O
in	O
myelopoiesis	O
,	O
transgenic	O
mice	O
expressing	O
PML/RARalpha	B-protein
were	O
engineered	O
.	O

A	O
full-length	O
PML/RARalpha	B-DNA
cDNA	I-DNA
driven	O
by	O
the	O
CD11b	B-DNA
promoter	I-DNA
was	O
expressed	O
in	O
transgenic	O
mice	O
.	O

Expression	O
was	O
confirmed	O
in	O
the	O
bone	O
marrow	O
with	O
a	O
reverse	O
transcription	O
PCR	O
assay	O
.	O

Basal	O
total	O
white	O
blood	O
cell	O
and	O
granulocyte	O
counts	O
did	O
not	O
appreciably	O
differ	O
between	O
PML/RARalpha	B-protein
transgenic	O
and	O
control	O
mice	O
.	O

Cell	O
sorter	O
analysis	O
of	O
CD11b+	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
revealed	O
similar	O
CD11b+	B-cell_type
populations	I-cell_type
in	O
transgenic	O
and	O
control	O
mice	O
.	O

However	O
,	O
in	O
vitro	O
clonal	O
growth	O
assays	O
performed	O
on	O
peripheral	O
blood	O
from	O
transgenic	O
versus	O
control	O
mice	O
revealed	O
a	O
marked	O
reduction	O
of	O
myeloid	B-cell_type
progenitors	I-cell_type
,	O
especially	O
in	O
those	O
responding	O
to	O
granulocyte/	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
.	O

Granulocyte/macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
and	O
kit	O
ligand	O
cotreatment	O
did	O
not	O
overcome	O
this	O
inhibition	O
.	O

Impaired	O
myelopoiesis	O
in	O
vivo	O
was	O
shown	O
by	O
stressing	O
these	O
mice	O
with	O
sublethal	O
irradiation	O
.	O

Following	O
irradiation	O
,	O
PML/RARalpha	B-protein
transgenic	O
mice	O
,	O
as	O
compared	O
with	O
controls	O
,	O
more	O
rapidly	O
depressed	O
peripheral	O
white	O
blood	O
cell	O
and	O
granulocyte	O
counts	O
.	O

As	O
expected	O
,	O
nearly	O
all	O
control	O
mice	O
(	O
94.4	O
%	O
)	O
survived	O
irradiation	O
,	O
yet	O
this	O
irradiation	O
was	O
lethal	O
to	O
45.8	O
%	O
of	O
PML/RARalpha	B-protein
transgenic	O
mice	O
.	O

Lethality	O
was	O
associated	O
with	O
more	O
severe	O
leukopenia	O
in	O
transgenic	O
versus	O
control	O
mice	O
.	O

Retinoic	O
acid	O
treatment	O
of	O
irradiated	O
PML/RARalpha	B-protein
mice	O
enhanced	O
granulocyte	B-cell_type
recovery	O
.	O

These	O
data	O
suggest	O
that	O
abnormal	O
myelopoiesis	O
due	O
to	O
PML/RARalpha	B-protein
expression	O
is	O
an	O
early	O
event	O
in	O
oncogenic	O
transformation	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

93	NULL
,	NULL
5p	NULL
.	NULL

7900-7904	NULL
,	NULL
July	NULL
1996	NULL
Medical	NULL
Sciences	NULL
Transgenic	NULL
expression	NULL
of	NULL
PML	NULL
/RARa	NULL
impairs	NULL
myelopoiesis	NULL
(	NULL
acute	NULL
promyelocytic	NULL
leukemia/transgene/all-trans	NULL
retinoic	NULL
acid	NULL
)	NULL
ELLEN	NULL
EARLY*	NULL
,	NULL
MALcoLM	NULL
A.	NULL
S.	NULL
MoorEt+	NULL
,	NULL
AKIRA	NULL
KakIZzUKA	NULL
$	NULL
!	NULL

,	NULL
KatHRYN	NULL
Nason-BURCHENAL*	NULL
,	NULL
PATRICK	NULL
MartTinN*	NULL
$	NULL
$	NULL
,	NULL
RonaLp	NULL
M.	NULL
Evans	NULL
$	NULL
,	NULL
anp	NULL
EtHan	NULL
Dmirrovsky*	NULL
**	NULL
tt	NULL
*Department	NULL
of	NULL
Medicine	NULL
,	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Medicine	NULL
,	NULL
**Molecular	NULL
Pharmacology	NULL
and	NULL
Therapeutics	NULL
Program	NULL
,	NULL
and	NULL
*Laboratory	NULL
of	NULL
Developmental	NULL
Hematopoiesis	NULL
,	NULL
£Cell	NULL
Biology	NULL
Program	NULL
,	NULL
Sloan-Kettering	NULL
Institute	NULL
,	NULL
Memorial	NULL
Sloan-Kettering	NULL
Cancer	NULL
Center	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
10021	NULL
;	NULL
and	NULL
$	NULL
Gene	NULL
Expression	NULL
Laboratory	NULL
,	NULL
The	NULL
Salk	NULL
Institute	NULL
for	NULL
Biological	NULL
Studies	NULL
and	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
92186	NULL
Contributed	NULL
by	NULL
Ronald	NULL
M.	NULL
Evans	NULL
,	NULL
April	NULL
17	NULL
,	NULL
1997	NULL
ABSTRACT	NULL
The	NULL
translocation	NULL
found	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
rearranges	NULL
the	NULL
promyelocytic	NULL
leukemia	NULL
gene	NULL
(	NULL
PML	NULL
)	NULL
on	NULL
chromosome	NULL
15	NULL
with	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
(	NULL
RAR	NULL
«	NULL
a	NULL
)	NULL
on	NULL
chromosome	NULL
17	NULL
.	NULL

This	NULL
yields	NULL
a	NULL
fusion	NULL
transcript	NULL
,	NULL
PML	NULL
/RARa	NULL
,	NULL
a	NULL
transcription	NULL
factor	NULL
with	NULL
reported	NULL
dominant	NULL
negative	NULL
functions	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
hormone	NULL
.	NULL

Clinical	NULL
remissions	NULL
induced	NULL
with	NULL
all-trans	NULL
retinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
treatment	NULL
in	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
are	NULL
linked	NULL
to	NULL
PML	NULL
expression	NULL
in	NULL
leukemic	NULL
cells	NULL
.	NULL

To	NULL
evaluate	NULL
the	NULL
PML	NULL
/RARa	NULL
role	NULL
in	NULL
myelopoiesis	NULL
,	NULL
transgenic	NULL
mice	NULL
expressing	NULL
PML	NULL
/RARa	NULL
«	NULL
were	NULL
engineered	NULL
.	NULL

A	NULL
full-length	NULL
PML/RARa	NULL
cDNA	NULL
driven	NULL
by	NULL
the	NULL
CD11ib	NULL
promoter	NULL
was	NULL
expressed	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

Expression	NULL
was	NULL
confirmed	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
with	NULL
a	NULL
reverse	NULL
transcription	NULL
PCR	NULL
assay	NULL
.	NULL

Basal	NULL
total	NULL
white	NULL
blood	NULL
cell	NULL
and	NULL
granulocyte	NULL
counts	NULL
did	NULL
not	NULL
appreciably	NULL
differ	NULL
between	NULL
PML	NULL
/	NULL
RARa	NULL
transgenic	NULL
and	NULL
control	NULL
mice	NULL
.	NULL

Cell	NULL
sorter	NULL
analysis	NULL
of	NULL
CD11b+*	NULL
bone	NULL
marrow	NULL
cells	NULL
revealed	NULL
similar	NULL
CD11b+	NULL
populations	NULL
in	NULL
transgenic	NULL
and	NULL
control	NULL
mice	NULL
.	NULL

However	NULL
,	NULL
in	NULL
vitro	NULL
clonal	NULL
growth	NULL
assays	NULL
performed	NULL
on	NULL
peripheral	NULL
blood	NULL
from	NULL
transgenic	NULL
versus	NULL
control	NULL
mice	NULL
revealed	NULL
a	NULL
marked	NULL
reduction	NULL
of	NULL
myeloid	NULL
progenitors	NULL
,	NULL
especially	NULL
in	NULL
those	NULL
responding	NULL
to	NULL
granulocyte/	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
.	NULL

Granulocyte/	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
and	NULL
kit	NULL
ligand	NULL
co-treatment	NULL
did	NULL
not	NULL
overcome	NULL
this	NULL
inhibition	NULL
.	NULL

Impaired	NULL
myelopoiesis	NULL
in	NULL
vivo	NULL
was	NULL
shown	NULL
by	NULL
stressing	NULL
these	NULL
mice	NULL
with	NULL
sublethal	NULL
irradiation	NULL
.	NULL

Following	NULL
irradiation	NULL
,	NULL
PML/RARa	NULL
transgenic	NULL
mice	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
controls	NULL
,	NULL
more	NULL
rapidly	NULL
depressed	NULL
peripheral	NULL
white	NULL
blod	NULL
cell	NULL
and	NULL
granulocyte	NULL
counts	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
nearly	NULL
all	NULL
control	NULL
mice	NULL
(	NULL
94.4	NULL
%	NULL
)	NULL
survived	NULL
irradiation	NULL
,	NULL
yet	NULL
this	NULL
irradiation	NULL
was	NULL
lethal	NULL
to	NULL
45.8	NULL
%	NULL
of	NULL
PML	NULL
/RARa	NULL
transgenic	NULL
mice	NULL
.	NULL

Lethality	NULL
was	NULL
associated	NULL
with	NULL
more	NULL
severe	NULL
leukopenia	NULL
in	NULL
transgenic	NULL
versus	NULL
control	NULL
mice	NULL
.	NULL

Retinoic	NULL
acid	NULL
treatment	NULL
of	NULL
irradiated	NULL
PML/RARa	NULL
mice	NULL
enhanced	NULL
granulocyte	NULL
recovery	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
abnormal	NULL
myelopoiesis	NULL
due	NULL
to	NULL
PML	NULL
/RARa	NULL
expression	NULL
is	NULL
an	NULL
early	NULL
event	NULL
in	NULL
oncogenic	NULL
transformation	NULL
.	NULL

In	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
(	NULL
APL	NULL
)	NULL
,	NULL
the	NULL
balanced	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
translocation	NULL
rearranges	NULL
the	NULL
promyelocytic	NULL
leukemia	NULL
gene	NULL
(	NULL
PML	NULL
)	NULL
on	NULL
chromosome	NULL
15	NULL
with	NULL
the	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
(	NULL
RARa	NULL
)	NULL
located	NULL
on	NULL
chromosome	NULL
17	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

This	NULL
translocation	NULL
leads	NULL
to	NULL
expression	NULL
of	NULL
a	NULL
fusion	NULL
transcript	NULL
,	NULL
PML/RAR	NULL
«	NULL
,	NULL
in	NULL
APL	NULL
cells	NULL
(	NULL
4-6	NULL
)	NULL
.	NULL

Variant	NULL
translocations	NULL
exist	NULL
and	NULL
also	NULL
involve	NULL
rearrangements	NULL
with	NULL
RARa	NULL
but	NULL
are	NULL
much	NULL
less	NULL
frequent	NULL
than	NULL
the	NULL
t	NULL
(	NULL
15	NULL
;	NULL
17	NULL
)	NULL
in	NULL
APL	NULL
(	NULL
7	NULL
)	NULL
.	NULL

PML	NULL
is	NULL
co-expressed	NULL
in	NULL
APL	NULL
cells	NULL
with	NULL
PML	NULL
and	NULL
RARa	NULL
(	NULL
4-6	NULL
)	NULL
.	NULL

All-trans	NULL
retinoic	NULL
acid	NULL
(	NULL
RA	NULL
)	NULL
treatment	NULL
of	NULL
APL	NULL
patients	NULL
causes	NULL
transient	NULL
complete	NULL
clinical	NULL
remissions	NULL
in	NULL
patients	NULL
whose	NULL
leukemic	NULL
cells	NULL
express	NULL
PML	NULL
/	NULL
RARa	NULL
(	NULL
6	NULL
,	NULL
8-10	NULL
)	NULL
.	NULL

Successful	NULL
RA	NULL
treatment	NULL
is	NULL
associated	NULL
with	NULL
in	NULL
vivo	NULL
leukemic	NULL
cell	NULL
maturation	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

It	NULL
is	NULL
postulated	NULL
that	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

7900	NULL
PML/RARa	NULL
functions	NULL
as	NULL
a	NULL
transcription	NULL
factor	NULL
with	NULL
dominant	NULL
negative	NULL
functions	NULL
exerted	NULL
on	NULL
the	NULL
RARa	NULL
or	NULL
PML	NULL
pathways	NULL
(	NULL
4	NULL
,	NULL
5	NULL
,	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

That	NULL
PML/RARa	NULL
has	NULL
an	NULL
inhibitory	NULL
role	NULL
in	NULL
APL	NULL
cells	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
finding	NULL
that	NULL
APL	NULL
cells	NULL
have	NULL
an	NULL
aberrant	NULL
nuclear	NULL
localization	NULL
of	NULL
PML	NULL
.	NULL

This	NULL
abnormality	NULL
is	NULL
reversed	NULL
by	NULL
RA	NULL
treatment	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
.	NULL

Direct	NULL
inhibitory	NULL
effects	NULL
of	NULL
PML	NULL
/RARa	NULL
in	NULL
myeloid	NULL
cells	NULL
was	NULL
shown	NULL
through	NULL
PML	NULL
expression	NULL
in	NULL
U937	NULL
or	NULL
HL-60	NULL
myeloid	NULL
leukemic	NULL
cells	NULL
(	NULL
11	NULL
,	NULL
15	NULL
)	NULL
.	NULL

In	NULL
NB4	NULL
cells	NULL
,	NULL
the	NULL
sole	NULL
APL	NULL
line	NULL
expressing	NULL
PML/RARa	NULL
and	NULL
inducing	NULL
a	NULL
mature	NULL
myeloid	NULL
phenotype	NULL
following	NULL
RA	NULL
treatment	NULL
(	NULL
16	NULL
)	NULL
,	NULL
over-expression	NULL
of	NULL
the	NULL
nonrearranged	NULL
alleles	NULL
,	NULL
RAR	NULL
«	NULL
,	NULL
or	NULL
PML	NULL
,	NULL
leads	NULL
to	NULL
growth	NULL
suppression	NULL
of	NULL
transfectants	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

This	NULL
growth	NULL
suppression	NULL
is	NULL
hypothesized	NULL
to	NULL
result	NULL
from	NULL
antagonism	NULL
of	NULL
PML	NULL
/RARa	NULL
function	NULL
in	NULL
these	NULL
APL	NULL
cells	NULL
.	NULL

Biologic	NULL
effects	NULL
of	NULL
an	NULL
expressed	NULL
dominant	NULL
negative	NULL
RARa	NULL
in	NULL
murine	NULL
myeloid	NULL
leukemic	NULL
and	NULL
progenitor	NULL
cells	NULL
have	NULL
been	NULL
reported	NULL
(	NULL
19	NULL
,	NULL
20	NULL
)	NULL
.	NULL

When	NULL
endogenous	NULL
RARa	NULL
activity	NULL
is	NULL
suppressed	NULL
in	NULL
myeloid	NULL
leukemic	NULL
cells	NULL
by	NULL
expression	NULL
of	NULL
a	NULL
dominant	NULL
negative	NULL
RARa	NULL
,	NULL
granulocyte/macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
-induced	NULL
neutrophil	NULL
differentiation	NULL
is	NULL
blocked	NULL
at	NULL
the	NULL
promyelocyte	NULL
stage	NULL
(	NULL
19	NULL
,	NULL
20	NULL
)	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
a	NULL
dominant	NULL
negative	NULL
RARa	NULL
to	NULL
inhibit	NULL
neutrophil	NULL
differentiation	NULL
at	NULL
the	NULL
promyelocyte	NULL
stage	NULL
was	NULL
also	NULL
reported	NULL
in	NULL
murine	NULL
primary	NULL
bone	NULL
marrow	NULL
cultures	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
blocked	NULL
promyelocytes	NULL
proliferated	NULL
continuously	NULL
as	NULL
a	NULL
GM-CSF-dependent	NULL
cell	NULL
line	NULL
but	NULL
were	NULL
induced	NULL
to	NULL
terminally	NULL
differentiate	NULL
into	NULL
neutrophils	NULL
following	NULL
RA	NULL
treatment	NULL
(	NULL
20	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
indicate	NULL
that	NULL
expression	NULL
of	NULL
a	NULL
dominant	NULL
negative	NULL
RARa	NULL
«	NULL
in	NULL
murine	NULL
myeloid	NULL
progenitors	NULL
alters	NULL
myeloid	NULL
maturation	NULL
and	NULL
may	NULL
represent	NULL
a	NULL
transformation	NULL
step	NULL
leading	NULL
to	NULL
leukemia	NULL
.	NULL

These	NULL
data	NULL
suggested	NULL
that	NULL
PML/RARa	NULL
expression	NULL
in	NULL
early	NULL
myeloid	NULL
cells	NULL
would	NULL
alter	NULL
myelopoiesis	NULL
.	NULL

The	NULL
present	NULL
study	NULL
was	NULL
undertaken	NULL
to	NULL
explore	NULL
the	NULL
growth	NULL
and	NULL
differentiation	NULL
effects	NULL
of	NULL
PML/RARa	NULL
«	NULL
in	NULL
bone	NULL
marrow	NULL
myeloid	NULL
cells	NULL
in	NULL
the	NULL
mouse	NULL
.	NULL

Mice	NULL
were	NULL
engineered	NULL
to	NULL
express	NULL
a	NULL
full-length	NULL
PML	NULL
cDNA	NULL
transgene	NULL
driven	NULL
by	NULL
the	NULL
CD11b	NULL
promoter	NULL
.	NULL

PML/RARa	NULL
expression	NULL
in	NULL
bone	NULL
marrow	NULL
cells	NULL
was	NULL
confirmed	NULL
using	NULL
a	NULL
reverse	NULL
transcription	NULL
(	NULL
RT	NULL
)	NULL
polymerase	NULL
chain	NULL
reaction	NULL
assay	NULL
.	NULL

Clonal	NULL
growth	NULL
assays	NULL
performed	NULL
using	NULL
peripheral	NULL
blood	NULL
and	NULL
bone	NULL
marrow	NULL
cells	NULL
isolated	NULL
from	NULL
transgenic	NULL
mice	NULL
reveal	NULL
PML	NULL
/RARa	NULL
expression	NULL
leads	NULL
to	NULL
impaired	NULL
myelopoiesis	NULL
.	NULL

Unexpectedly	NULL
,	NULL
transgenic	NULL
mice	NULL
display	NULL
marked	NULL
sensi-	NULL
Abbreviations	NULL
:	NULL
APL	NULL
,	NULL
acute	NULL
promyelocytic	NULL
leukemia	NULL
;	NULL
PML	NULL
,	NULL
promyelocytic	NULL
leukemia	NULL
gene	NULL
;	NULL
RARa	NULL
,	NULL
retinoic	NULL
acid	NULL
receptor	NULL
a	NULL
;	NULL
RA	NULL
,	NULL
all-frans-retinoic	NULL
acid	NULL
;	NULL
GM-CSF	NULL
,	NULL
granulocyte/macrophage	NULL
colony-stimulating	NULL
factor	NULL
;	NULL
RT	NULL
,	NULL
reverse	NULL
transcription	NULL
;	NULL
DMSO	NULL
,	NULL
dimethyl	NULL
sulfoxide	NULL
;	NULL
HPP-CFC	NULL
;	NULL
high	NULL
proliferative	NULL
potential	NULL
colony-forming	NULL
cell	NULL
;	NULL
KL	NULL
,	NULL
kit	NULL
ligand	NULL
;	NULL
CFU-GM	NULL
,	NULL
colony	NULL
forming	NULL
unit-granulocyte/macrophage	NULL
;	NULL
CFU-GEMM	NULL
,	NULL
mixed	NULL
CFU	NULL
;	NULL
LPP-CFC	NULL
,	NULL
low	NULL
proliferative	NULL
potential	NULL
colony	NULL
forming	NULL
cell	NULL
.	NULL

``	NULL
Present	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Pharmacology	NULL
,	NULL
Kyoto	NULL
University	NULL
Faculty	NULL
of	NULL
Medicine	NULL
,	NULL
Kyoto	NULL
,	NULL
Japan	NULL
.	NULL

t	NULL
!	NULL

To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
at	NULL
Memorial	NULL
Sloan-Kettering	NULL
Cancer	NULL
Center	NULL
,	NULL
1275	NULL
York	NULL
Avenue	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
10021	NULL
.	NULL

#	NULL
#	NULL
CNRS	NULL
URA	NULL
1160	NULL
Laboratoire	NULL
d'Oncologie	NULL
Moleculaire	NULL
,	NULL
1	NULL
,	NULL
Rue	NULL
Calmette	NULL
,	NULL
Institut	NULL
Pasteur	NULL
de	NULL
Lille	NULL
,	NULL
France	NULL
,	NULL
59019	NULL
.	NULL

Medical	NULL
Sciences	NULL
:	NULL
Early	NULL
et	NULL
al	NULL
.	NULL

tivity	NULL
to	NULL
sublethal	NULL
radiation	NULL
with	NULL
increased	NULL
depression	NULL
of	NULL
total	NULL
white	NULL
blood	NULL
cell	NULL
(	NULL
WBC	NULL
)	NULL
and	NULL
granulocyte	NULL
counts	NULL
.	NULL

The	NULL
recovery	NULL
of	NULL
granulocytes	NULL
and	NULL
leukocytes	NULL
was	NULL
enhanced	NULL
by	NULL
RA	NULL
treatment	NULL
of	NULL
transgenic	NULL
mice	NULL
.	NULL

These	NULL
findings	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
view	NULL
that	NULL
PML	NULL
/RARa	NULL
inhibits	NULL
myelopoiesis	NULL
and	NULL
directly	NULL
contributes	NULL
to	NULL
transformation	NULL
of	NULL
myeloid	NULL
cells	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
RT-PCR	NULL
Assay	NULL
and	NULL
Southern	NULL
Analysis	NULL
.	NULL

RNA	NULL
and	NULL
genomic	NULL
DNA	NULL
were	NULL
purified	NULL
from	NULL
NB4	NULL
cells	NULL
and	NULL
the	NULL
bone	NULL
marrow	NULL
of	NULL
control	NULL
and	NULL
transgenic	NULL
PML/RARa	NULL
mice	NULL
using	NULL
guanidine	NULL
thiocyanate	NULL
and	NULL
standard	NULL
techniques	NULL
(	NULL
21	NULL
)	NULL
.	NULL

PML/RARa	NULL
expression	NULL
was	NULL
assayed	NULL
in	NULL
total	NULL
RNA	NULL
isolated	NULL
from	NULL
harvested	NULL
bone	NULL
marrow	NULL
.	NULL

Nested	NULL
primers	NULL
and	NULL
an	NULL
RT-PCR	NULL
assay	NULL
were	NULL
used	NULL
with	NULL
established	NULL
techniques	NULL
optimized	NULL
for	NULL
detection	NULL
of	NULL
PML	NULL
/	NULL
RARa	NULL
mRNA	NULL
in	NULL
APL	NULL
cells	NULL
(	NULL
6	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Southern	NULL
analysis	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
22	NULL
)	NULL
.	NULL

PML/RARa	NULL
Transgenic	NULL
Mice	NULL
.	NULL

The	NULL
PML/RARa	NULL
expression	NULL
vector	NULL
was	NULL
constructed	NULL
using	NULL
a	NULL
full-length	NULL
PML/RARa	NULL
cDNA	NULL
(	NULL
4	NULL
)	NULL
cloned	NULL
into	NULL
the	NULL
NotI	NULL
site	NULL
of	NULL
a	NULL
Bluescript	NULL
(	NULL
Stratagene	NULL
)	NULL
plasmid	NULL
.	NULL

This	NULL
was	NULL
gel-purified	NULL
after	NULL
digestion	NULL
with	NULL
Bg/II	NULL
and	NULL
Xbal	NULL
.	NULL

A	NULL
Hind	NULL
!	NULL

III/Smal	NULL
fragment	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
(	NULL
29	NULL
)	NULL
was	NULL
ligated	NULL
at	NULL
the	NULL
HindIII	NULL
site	NULL
of	NULL
a	NULL
Bluescript	NULL
SK~-	NULL
plasmid	NULL
containing	NULL
a	NULL
0.7-kb	NULL
Xbal/EcoRI	NULL
fragment	NULL
of	NULL
the	NULL
SV40	NULL
Poly	NULL
(	NULL
A	NULL
)	NULL
sequence	NULL
.	NULL

The	NULL
vector	NULL
was	NULL
engineered	NULL
by	NULL
bluntly	NULL
ligating	NULL
the	NULL
5	NULL
'	NULL
BgilI	NULL
site	NULL
in	NULL
the	NULL
PML/RARa	NULL
fragment	NULL
to	NULL
the	NULL
SmaI	NULL
site	NULL
in	NULL
the	NULL
plasmid	NULL
and	NULL
ligating	NULL
the	NULL
3	NULL
'	NULL
Xbal	NULL
site	NULL
of	NULL
this	NULL
fragment	NULL
to	NULL
an	NULL
Xbal	NULL
site	NULL
in	NULL
the	NULL
plasmid	NULL
backbone	NULL
.	NULL

Transgenic	NULL
mice	NULL
were	NULL
engineered	NULL
using	NULL
standard	NULL
techniques	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Founder	NULL
mice	NULL
were	NULL
mated	NULL
to	NULL
ICR	NULL
Swiss	NULL
or	NULL
non-Swiss	NULL
mice	NULL
.	NULL

Controls	NULL
were	NULL
identical	NULL
to	NULL
transgenic	NULL
mice	NULL
but	NULL
did	NULL
not	NULL
express	NULL
PML	NULL
/	NULL
RARa	NULL
.	NULL

An	NULL
independent	NULL
PML/RARa	NULL
line	NULL
was	NULL
derived	NULL
to	NULL
exclude	NULL
genetic	NULL
heterogeneity	NULL
as	NULL
responsible	NULL
for	NULL
an	NULL
observed	NULL
phe-notype	NULL
.	NULL

Mice	NULL
were	NULL
aged	NULL
8-12	NULL
weeks	NULL
and	NULL
were	NULL
sex	NULL
and	NULL
weight	NULL
matched	NULL
.	NULL

An	NULL
approved	NULL
institutional	NULL
animal	NULL
care	NULL
and	NULL
use	NULL
committee	NULL
protocol	NULL
was	NULL
used	NULL
.	NULL

Radiation	NULL
Protocols	NULL
.	NULL

Control	NULL
and	NULL
transgenic	NULL
mice	NULL
received	NULL
y	NULL
irradiation	NULL
from	NULL
a	NULL
cesium	NULL
source	NULL
(	NULL
600	NULL
rad/mouse	NULL
)	NULL
.	NULL

This	NULL
caused	NULL
negligible	NULL
lethality	NULL
,	NULL
transient	NULL
anemia	NULL
,	NULL
thrombocytope-nia	NULL
,	NULL
granulocytopenia	NULL
,	NULL
and	NULL
minimal	NULL
weight	NULL
loss	NULL
or	NULL
other	NULL
symptoms	NULL
in	NULL
control	NULL
mice	NULL
.	NULL

When	NULL
radiation-induced	NULL
leukopenia	NULL
developed	NULL
,	NULL
WBC	NULL
and	NULL
granulocyte	NULL
counts	NULL
,	NULL
hemoglobin	NULL
,	NULL
hematocrit	NULL
,	NULL
and	NULL
platelet	NULL
counts	NULL
were	NULL
measured	NULL
generally	NULL
daily	NULL
,	NULL
until	NULL
WBC	NULL
recovery	NULL
.	NULL

Granulocytes	NULL
were	NULL
counted	NULL
after	NULL
crystal	NULL
violet	NULL
staining	NULL
of	NULL
peripheral	NULL
blood	NULL
smears	NULL
.	NULL

To	NULL
limit	NULL
phlebot-omy	NULL
,	NULL
groups	NULL
of	NULL
six	NULL
or	NULL
12	NULL
mice	NULL
had	NULL
base-line	NULL
hematologic	NULL
parameters	NULL
measured	NULL
.	NULL

After	NULL
radiation-induced	NULL
leukopenia	NULL
,	NULL
three	NULL
control	NULL
or	NULL
transgenic	NULL
mice	NULL
had	NULL
hematologic	NULL
parameters	NULL
measured	NULL
generally	NULL
daily	NULL
.	NULL

Mice	NULL
were	NULL
rotated	NULL
for	NULL
these	NULL
measurements	NULL
.	NULL

Results	NULL
were	NULL
correlated	NULL
with	NULL
survival	NULL
after	NULL
irradiation	NULL
.	NULL

Whether	NULL
RA	NULL
(	NULL
Sigma	NULL
)	NULL
limited	NULL
radiation-induced	NULL
myelo-suppression	NULL
in	NULL
transgenic	NULL
mice	NULL
was	NULL
studied	NULL
.	NULL

Twenty-four	NULL
PML/RARa	NULL
transgenic	NULL
mice	NULL
were	NULL
each	NULL
irradiated	NULL
with	NULL
600	NULL
rad	NULL
.	NULL

The	NULL
day	NULL
before	NULL
and	NULL
of	NULL
irradiation	NULL
,	NULL
12	NULL
transgenic	NULL
mice	NULL
were	NULL
each	NULL
administered	NULL
dimethyl	NULL
sulfoxide	NULL
(	NULL
DMSO	NULL
,	NULL
Sigma	NULL
)	NULL
as	NULL
a	NULL
40-ul	NULL
i.p	NULL
.	NULL

injection	NULL
.	NULL

The	NULL
day	NULL
before	NULL
and	NULL
of	NULL
irradiation	NULL
,	NULL
12	NULL
other	NULL
transgenic	NULL
mice	NULL
were	NULL
each	NULL
administered	NULL
RA	NULL
(	NULL
1	NULL
mg	NULL
ip	NULL
.	NULL
)	NULL

dissolved	NULL
in	NULL
the	NULL
same	NULL
DMSO	NULL
volume	NULL
as	NULL
controls	NULL
.	NULL

Clonal	NULL
Growth	NULL
and	NULL
Cell	NULL
Sorter	NULL
Assays	NULL
.	NULL

Bone	NULL
marrow	NULL
from	NULL
untreated	NULL
or	NULL
24-h	NULL
post	NULL
5-fluorouracil	NULL
treated	NULL
mice	NULL
were	NULL
har-vested	NULL
.	NULL

Early	NULL
hematopoietic	NULL
progenitors	NULL
were	NULL
detected	NULL
in	NULL
primary	NULL
and	NULL
7-day	NULL
``	NULL
delta	NULL
``	NULL
culture	NULL
generated-secondary	NULL
high	NULL
proliferative	NULL
potential	NULL
colony-forming	NULL
cells	NULL
(	NULL
HPP-CFCs	NULL
)	NULL
using	NULL
interleukin-3	NULL
,	NULL
KL	NULL
,	NULL
and	NULL
established	NULL
techniques	NULL
(	NULL
24-26	NULL
)	NULL
.	NULL

For	NULL
5-fluorouracil-untreated	NULL
mice	NULL
,	NULL
primary	NULL
cultures	NULL
were	NULL
performed	NULL
using	NULL
peripheral	NULL
blood	NULL
or	NULL
bone	NULL
marrow	NULL
with	NULL
5	NULL
x	NULL
10+	NULL
cells/ml	NULL
supplemented	NULL
with	NULL
or	NULL
without	NULL
cytokines	NULL
.	NULL

Bone	NULL
marrow	NULL
cultures	NULL
were	NULL
used	NULL
for	NULL
colony	NULL
forming	NULL
unit-granulocyte/	NULL
macrophage	NULL
(	NULL
CFU-GM	NULL
)	NULL
and	NULL
burst	NULL
forming	NULL
unit-erythroid	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
7901	NULL
measurements	NULL
.	NULL

Low	NULL
proliferative	NULL
potential	NULL
colony	NULL
forming	NULL
cells	NULL
(	NULL
LPP-CFCs	NULL
)	NULL
were	NULL
assayed	NULL
with	NULL
2.5	NULL
X	NULL
10°	NULL
bone	NULL
marrow	NULL
cells	NULL
.	NULL

Cultures	NULL
were	NULL
scored	NULL
at	NULL
7	NULL
days	NULL
for	NULL
CFU-GMs	NULL
or	NULL
LPP-CFCs	NULL
.	NULL

HPP-CFC	NULL
colonies	NULL
with	NULL
minimum	NULL
diameter	NULL
of	NULL
0.5	NULL
mm	NULL
were	NULL
scored	NULL
at	NULL
10	NULL
days	NULL
.	NULL

Assays	NULL
were	NULL
performed	NULL
in	NULL
triplicate	NULL
and	NULL
confirmed	NULL
in	NULL
at	NULL
least	NULL
triplicate	NULL
independent	NULL
experiments	NULL
.	NULL

The	NULL
recombinant	NULL
cytokines	NULL
were	NULL
'	NULL
murine	NULL
KL	NULL
at	NULL
20	NULL
ng/ml	NULL
(	NULL
Immunex	NULL
)	NULL
,	NULL
murine	NULL
GM-CSF	NULL
at	NULL
10	NULL
ng/ml	NULL
(	NULL
Immunex	NULL
)	NULL
,	NULL
murine	NULL
inter-leukin-3	NULL
(	NULL
Intergen	NULL
)	NULL
at	NULL
20	NULL
ng/ml	NULL
,	NULL
human	NULL
G-CSF	NULL
(	NULL
Amgen	NULL
Biologicals	NULL
)	NULL
at	NULL
1000	NULL
units/ml	NULL
,	NULL
human	NULL
M-CSF	NULL
(	NULL
Cetus	NULL
)	NULL
at	NULL
1000	NULL
units/ml	NULL
,	NULL
and	NULL
human	NULL
erythropoietin	NULL
(	NULL
Amgen	NULL
)	NULL
at	NULL
2	NULL
units/ml	NULL
.	NULL

Cell	NULL
sorter	NULL
assays	NULL
compared	NULL
CD11b*	NULL
populations	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
of	NULL
these	NULL
mice	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
rat	NULL
anti-mouse	NULL
CD11b	NULL
(	NULL
MAC-1	NULL
)	NULL
fluorescein	NULL
isothiocyanate-conjugated	NULL
antibody	NULL
or	NULL
an	NULL
isotype	NULL
matched	NULL
,	NULL
fluorescein	NULL
iso-thiocyanate-labeled	NULL
,	NULL
control	NULL
antibody	NULL
(	NULL
Caltag	NULL
)	NULL
.	NULL

Red	NULL
blood	NULL
cells	NULL
were	NULL
lysed	NULL
wtih	NULL
potassium	NULL
acetate	NULL
.	NULL

Assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
17	NULL
)	NULL
.	NULL

RESULTS	NULL
Transgenic	NULL
PML	NULL
expression	NULL
was	NULL
confirmed	NULL
using	NULL
an	NULL
RT-PCR	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
expected	NULL
short	NULL
form	NULL
of	NULL
PML	NULL
/	NULL
RARa	NULL
mRNA	NULL
(	NULL
6	NULL
)	NULL
was	NULL
found	NULL
in	NULL
bone	NULL
marrow	NULL
of	NULL
transgenic	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
but	NULL
not	NULL
control	NULL
mice	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

As	NULL
a	NULL
positive	NULL
control	NULL
,	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
the	NULL
APL	NULL
cell	NULL
line	NULL
(	NULL
NB4	NULL
)	NULL
that	NULL
expresses	NULL
the	NULL
long	NULL
form	NULL
of	NULL
PML	NULL
/RARa	NULL
(	NULL
6	NULL
,	NULL
16	NULL
)	NULL
along	NULL
with	NULL
several	NULL
splice	NULL
variants	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Southern	NULL
analysis	NULL
was	NULL
performed	NULL
using	NULL
genomic	NULL
DNA	NULL
from	NULL
a	NULL
representative	NULL
transgenic	NULL
mouse	NULL
to	NULL
confirm	NULL
the	NULL
entire	NULL
PML	NULL
cDNA	NULL
was	NULL
present	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

A	NULL
full-length	NULL
PML/RARa	NULL
cDNA	NULL
was	NULL
cloned	NULL
and	NULL
sequenced	NULL
from	NULL
this	NULL
mouse	NULL
.	NULL

No	NULL
sequence	NULL
additions	NULL
,	NULL
deletions	NULL
,	NULL
or	NULL
substitutions	NULL
were	NULL
identified	NULL
in	NULL
this	NULL
cDNA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
begin	NULL
to	NULL
characterize	NULL
the	NULL
phenotype	NULL
present	NULL
in	NULL
this	NULL
transgenic	NULL
line	NULL
,	NULL
clonal	NULL
growth	NULL
assays	NULL
were	NULL
performed	NULL
on	NULL
bone	NULL
marrow	NULL
and	NULL
peripheral	NULL
blood	NULL
.	NULL

As	NULL
expressed	NULL
per	NULL
femur	NULL
,	NULL
in	NULL
wild-type	NULL
versus	NULL
transgenic	NULL
bone	NULL
marrow	NULL
,	NULL
total	NULL
burst	NULL
forming	NULL
unit-erythroid	NULL
(	NULL
4047	NULL
+	NULL
3059	NULL
SEM	NULL
versus	NULL
3814	NULL
+	NULL
187	NULL
SEM	NULL
)	NULL
and	NULL
CFU-GEMM	NULL
(	NULL
1017	NULL
+	NULL
276	NULL
SEM	NULL
versus	NULL
998	NULL
+	NULL
276	NULL
SEM	NULL
)	NULL
numbers	NULL
did	NULL
not	NULL
appreciably	NULL
differ	NULL
while	NULL
CFU-GM	NULL
numbers	NULL
were	NULL
slightly	NULL
higher	NULL
in	NULL
wild-type	NULL
mice	NULL
(	NULL
37,050	NULL
+	NULL
21,739	NULL
SEM	NULL
versus	NULL
29,386	NULL
+	NULL
566	NULL
SEM	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
peripheral	NULL
blood	NULL
cells	NULL
derived	NULL
from	NULL
PML	NULL
transgenic	NULL
but	NULL
not	NULL
wild-type	NULL
controls	NULL
displayed	NULL
a	NULL
blunted	NULL
clonal	NULL
growth	NULL
response	NULL
to	NULL
GM-CSF	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
P	NULL
value	NULL
=	NULL
0.007	NULL
,	NULL
two-tailed	NULL
Student	NULL
's	NULL
¢	NULL
test	NULL
)	NULL
.	NULL

This	NULL
cytokine	NULL
is	NULL
active	NULL
in	NULL
the	NULL
same	NULL
myeloid	NULL
populations	NULL
in	NULL
which	NULL
the	NULL
CD11b	NULL
promoter	NULL
is	NULL
active	NULL
(	NULL
27-30	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
an	NULL
inhibited	NULL
bp	NULL
_	NULL
.	NULL

1000	NULL
-	NULL
800	NULL
-	NULL
600	NULL
-	NULL
500	NULL
-	NULL
400	NULL
-	NULL
300	NULL
-	NULL
200	NULL
1~2	NULL
``	NULL
3	NULL
«	NULL
B	NULL
``	NULL
6	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

The	NULL
RT-PCR	NULL
assay	NULL
for	NULL
PML/RARa	NULL
mRNA	NULL
expression	NULL
in	NULL
PML	NULL
/RARa	NULL
transgenic	NULL
and	NULL
control	NULL
mice	NULL
.	NULL

To	NULL
exclude	NULL
contaminating	NULL
genomic	NULL
DNA	NULL
as	NULL
responsible	NULL
for	NULL
the	NULL
PML/RARa	NULL
signal	NULL
,	NULL
RNA	NULL
samples	NULL
were	NULL
treated	NULL
with	NULL
RNase-free	NULL
DNAse	NULL
.	NULL

The	NULL
lanes	NULL
represent	NULL
total	NULL
RNA	NULL
from	NULL
the	NULL
NB4	NULL
cell	NULL
line	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
pooled	NULL
bone	NULL
marrow	NULL
from	NULL
control	NULL
mice	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
or	NULL
pooled	NULL
bone	NULL
marrow	NULL
from	NULL
PML/RARa	NULL
transgenic	NULL
mice	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

No	NULL
RT	NULL
was	NULL
added	NULL
to	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
,	NULL
and	NULL
5	NULL
,	NULL
while	NULL
RT	NULL
was	NULL
added	NULL
to	NULL
the	NULL
reactions	NULL
of	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
6	NULL
.	NULL

These	NULL
species	NULL
were	NULL
size-fractionated	NULL
on	NULL
a	NULL
0.8	NULL
%	NULL
agarose	NULL
gel	NULL
,	NULL
and	NULL
molecular	NULL
weight	NULL
markers	NULL
are	NULL
depicted	NULL
in	NULL
base	NULL
pairs	NULL
.	NULL

7902	NULL
Medical	NULL
Sciences	NULL
:	NULL
Early	NULL
et	NULL
al	NULL
.	NULL

A	NULL
200	NULL
M	NULL
Wild-type	NULL
Transgene	NULL
u	NULL
.0	NULL
5	NULL
100	NULL
|-e	NULL
]	NULL
O	NULL
0	NULL
Control	NULL
GM	NULL
GM	NULL
+	NULL
KL	NULL
Treatments	NULL
B	NULL
IgG	NULL
CD1ib	NULL
8-	NULL
$	NULL
-	NULL
g1	NULL
3	NULL
s	NULL
+	NULL
2	NULL
€	NULL
e4	NULL
>	NULL
18	NULL
ao	NULL
(	NULL
¢	NULL
it	NULL
aot	NULL
©	NULL
8	NULL
O	NULL
§	NULL
Transgene	NULL
§1	NULL
B	NULL
B	NULL
-B	NULL
18	NULL
ao	NULL
)	NULL
t	NULL
as	NULL
ast	NULL
1	NULL
ao	NULL
!	NULL

ad	NULL
aot	NULL
aot	NULL
Fluorescence	NULL
Intensity	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Clonal	NULL
growth	NULL
assays	NULL
performed	NULL
on	NULL
peripheral	NULL
blood	NULL
cells	NULL
derived	NULL
from	NULL
wild-type	NULL
and	NULL
PML/RARa	NULL
transgenic	NULL
mice	NULL
.	NULL

This	NULL
assay	NULL
reveals	NULL
the	NULL
normal	NULL
stimulatory	NULL
response	NULL
of	NULL
wild-type	NULL
cells	NULL
to	NULL
the	NULL
cytokine	NULL
GM-CSF	NULL
and	NULL
an	NULL
impaired	NULL
response	NULL
of	NULL
transgenic	NULL
cells	NULL
.	NULL

GM-CSF	NULL
co-treatment	NULL
with	NULL
KL	NULL
did	NULL
not	NULL
overcome	NULL
this	NULL
inhibition	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
no	NULL
cytokines	NULL
were	NULL
added	NULL
.	NULL

The	NULL
results	NULL
depict	NULL
representative	NULL
findings	NULL
from	NULL
triplicate	NULL
clonal	NULL
growth	NULL
assays	NULL
conducted	NULL
in	NULL
five	NULL
independent	NULL
wild-type	NULL
and	NULL
five	NULL
PML	NULL
/RARa	NULL
transgenic	NULL
mice	NULL
.	NULL

Colonies	NULL
per	NULL
4	NULL
x	NULL
10+	NULL
cells	NULL
plated	NULL
are	NULL
reported	NULL
with	NULL
standard	NULL
deviation	NULL
bars	NULL
indicated	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
cell	NULL
sorter	NULL
analysis	NULL
for	NULL
CD11b*	NULL
cells	NULL
in	NULL
wild-type	NULL
and	NULL
PML/RARa	NULL
transgenic	NULL
bone	NULL
marrow	NULL
each	NULL
isolated	NULL
from	NULL
representative	NULL
mice	NULL
.	NULL

The	NULL
control	NULL
antibody	NULL
is	NULL
isotype	NULL
matched	NULL
,	NULL
not	NULL
recognizing	NULL
CD11b	NULL
.	NULL

A	NULL
similar	NULL
cell	NULL
number	NULL
and	NULL
fluorescence	NULL
intensity	NULL
is	NULL
shown	NULL
for	NULL
CD11b*t	NULL
populations	NULL
in	NULL
wild-type	NULL
versus	NULL
PML/RARa	NULL
transgenic	NULL
bone	NULL
marrow	NULL
.	NULL

clonal	NULL
growth	NULL
response	NULL
was	NULL
also	NULL
observed	NULL
after	NULL
addition	NULL
of	NULL
either	NULL
G-CSF	NULL
or	NULL
M-CSF	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

GM-CSF	NULL
co-treatment	NULL
with	NULL
KL	NULL
did	NULL
not	NULL
overcome	NULL
this	NULL
inhibition	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
P	NULL
value	NULL
=	NULL
0.009	NULL
,	NULL
two-tailed	NULL
Student	NULL
's	NULL
¢	NULL
test	NULL
)	NULL
.	NULL

Clonal	NULL
growth	NULL
assays	NULL
were	NULL
simultaneously	NULL
performed	NULL
with	NULL
bone	NULL
marrow	NULL
from	NULL
five	NULL
control	NULL
and	NULL
five	NULL
PML/RARa	NULL
transgenic	NULL
mice	NULL
following	NULL
stimulation	NULL
with	NULL
GM-CSF	NULL
or	NULL
GM-CSF	NULL
plus	NULL
KL	NULL
.	NULL

When	NULL
findings	NULL
are	NULL
expressed	NULL
per	NULL
femur	NULL
,	NULL
bone	NULL
marrow	NULL
clonal	NULL
growth	NULL
was	NULL
only	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
slightly	NULL
higher	NULL
in	NULL
control	NULL
versus	NULL
transgenic	NULL
mice	NULL
following	NULL
treatments	NULL
with	NULL
GM-CSF	NULL
(	NULL
10,555	NULL
+	NULL
1377	NULL
SEM	NULL
versus	NULL
9986	NULL
+	NULL
2226	NULL
SEM	NULL
)	NULL
or	NULL
GM-CSF	NULL
plus	NULL
KL	NULL
(	NULL
11,505	NULL
+	NULL
1595	NULL
SEM	NULL
versus	NULL
10,978	NULL
+	NULL
2105	NULL
SEM	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
from	NULL
a	NULL
second	NULL
transgenic	NULL
line	NULL
established	NULL
from	NULL
an	NULL
independent	NULL
founder	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

_	NULL
It	NULL
is	NULL
unlikely	NULL
the	NULL
CD11b	NULL
driven	NULL
PML/RARa	NULL
transgene	NULL
is	NULL
expressed	NULL
in	NULL
the	NULL
earliest	NULL
myeloid	NULL
progenitors	NULL
(	NULL
27-30	NULL
)	NULL
.	NULL

Stem	NULL
cell	NULL
assays	NULL
(	NULL
HPP-CFC	NULL
)	NULL
were	NULL
performed	NULL
with	NULL
bone	NULL
marrow	NULL
harvested	NULL
from	NULL
PML	NULL
transgenic	NULL
or	NULL
wild-type	NULL
mice	NULL
to	NULL
confirm	NULL
that	NULL
peripheral	NULL
blood	NULL
findings	NULL
did	NULL
not	NULL
reflect	NULL
observed	NULL
changes	NULL
in	NULL
myeloid	NULL
stem	NULL
cells	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
responses	NULL
of	NULL
these	NULL
early	NULL
myeloid	NULL
progenitors	NULL
to	NULL
GM-CSF	NULL
or	NULL
GM-CSF	NULL
plus	NULL
KL	NULL
were	NULL
normal	NULL
.	NULL

Thus	NULL
,	NULL
comparable	NULL
LPP-CFC	NULL
and	NULL
HPP-CFC	NULL
numbers	NULL
were	NULL
isolated	NULL
from	NULL
5	NULL
wild-type	NULL
and	NULL
5	NULL
PML	NULL
transgenic	NULL
mice	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similar	NULL
findings	NULL
were	NULL
obtained	NULL
in	NULL
a	NULL
second	NULL
independent	NULL
experiment	NULL
,	NULL
indicating	NULL
that	NULL
changes	NULL
in	NULL
stem	NULL
cell	NULL
numbers	NULL
do	NULL
not	NULL
account	NULL
for	NULL
altered	NULL
GM-CSF	NULL
response	NULL
in	NULL
peripheral	NULL
blood	NULL
from	NULL
the	NULL
transgenic	NULL
line	NULL
.	NULL

Similarly	NULL
,	NULL
search	NULL
for	NULL
changes	NULL
in	NULL
CD11b*	NULL
populations	NULL
using	NULL
cell	NULL
sorter	NULL
analysis	NULL
failed	NULL
to	NULL
reveal	NULL
significant	NULL
differences	NULL
between	NULL
control	NULL
and	NULL
transgenic	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Similar	NULL
findings	NULL
were	NULL
obtained	NULL
in	NULL
22	NULL
wild-type	NULL
and	NULL
20	NULL
PML/RARa	NULL
transgenic	NULL
mice	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
numbers	NULL
of	NULL
CD11b*	NULL
bone	NULL
marrow	NULL
cells	NULL
do	NULL
not	NULL
explain	NULL
altered	NULL
GM-CSF	NULL
cellular	NULL
response	NULL
of	NULL
transgenic	NULL
mice	NULL
.	NULL

To	NULL
exclude	NULL
other	NULL
changes	NULL
due	NULL
to	NULL
PML	NULL
expression	NULL
,	NULL
necropsies	NULL
were	NULL
performed	NULL
in	NULL
eight	NULL
transgenic	NULL
mice	NULL
and	NULL
were	NULL
compared	NULL
with	NULL
findings	NULL
obtained	NULL
from	NULL
eight	NULL
control	NULL
mice	NULL
.	NULL

No	NULL
gross	NULL
abnormalities	NULL
were	NULL
observed	NULL
in	NULL
these	NULL
transgenic	NULL
or	NULL
control	NULL
mice	NULL
.	NULL

Histopathologic	NULL
studies	NULL
were	NULL
performed	NULL
on	NULL
the	NULL
spleen	NULL
and	NULL
bone	NULL
marrow	NULL
of	NULL
mice	NULL
.	NULL

No	NULL
abnormalities	NULL
were	NULL
observed	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

24	NULL
,	NULL
peripheral	NULL
blood	NULL
clonal	NULL
growth	NULL
assays	NULL
reveal	NULL
an	NULL
altered	NULL
cytokine	NULL
response	NULL
of	NULL
PML	NULL
/RARa	NULL
«	NULL
expressing	NULL
cells	NULL
.	NULL

To	NULL
evaluate	NULL
whether	NULL
stressing	NULL
the	NULL
bone	NULL
marrow	NULL
of	NULL
mice	NULL
uncovers	NULL
a	NULL
phenotype	NULL
,	NULL
groups	NULL
of	NULL
wild-type	NULL
and	NULL
transgenic	NULL
mice	NULL
(	NULL
matched	NULL
for	NULL
age	NULL
,	NULL
sex	NULL
,	NULL
and	NULL
weight	NULL
)	NULL
were	NULL
each	NULL
irradiated	NULL
with	NULL
sublethal	NULL
total	NULL
body	NULL
irradiation	NULL
(	NULL
600	NULL
rad	NULL
,	NULL
single	NULL
dose	NULL
)	NULL
.	NULL

Mice	NULL
were	NULL
monitored	NULL
at	NULL
indicated	NULL
time	NULL
points	NULL
for	NULL
radiation-induced	NULL
changes	NULL
in	NULL
hematologic	NULL
parameters	NULL
,	NULL
including	NULL
total	NULL
WBC	NULL
and	NULL
granulocyte	NULL
counts	NULL
.	NULL

Results	NULL
of	NULL
a	NULL
representative	NULL
experiment	NULL
appear	NULL
in	NULL
Fig	NULL
.	NULL

34	NULL
.	NULL

This	NULL
demonstrates	NULL
that	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
controls	NULL
,	NULL
PML	NULL
/RARa	NULL
«	NULL
transgenic	NULL
mice	NULL
have	NULL
a	NULL
more	NULL
rapid	NULL
and	NULL
sustained	NULL
decline	NULL
in	NULL
total	NULL
WBC	NULL
counts	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
.	NULL

The	NULL
period	NULL
of	NULL
severe	NULL
granulocytopenia	NULL
(	NULL
<	NULL
250	NULL
per	NULL
wl	NULL
)	NULL
was	NULL
longer	NULL
in	NULL
transgenic	NULL
than	NULL
control	NULL
mice	NULL
(	NULL
8	NULL
versus	NULL
5	NULL
days	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
nearly	NULL
all	NULL
control	NULL
(	NULL
94.4	NULL
%	NULL
,	NULL
17	NULL
of	NULL
18	NULL
)	NULL
mice	NULL
survived	NULL
irradiation	NULL
.	NULL

Fig	NULL
.	NULL

3B	NULL
reflects	NULL
pooled	NULL
findings	NULL
from	NULL
two	NULL
independent	NULL
experiments	NULL
using	NULL
12	NULL
and	NULL
six	NULL
wild-type	NULL
mice	NULL
.	NULL

In	NULL
marked	NULL
contrast	NULL
,	NULL
experiments	NULL
with	NULL
24	NULL
PML	NULL
/RARa	NULL
transgenic	NULL
mice	NULL
(	NULL
represent-ing	NULL
pooled	NULL
results	NULL
from	NULL
two	NULL
independent	NULL
experiments	NULL
each	NULL
with	NULL
12	NULL
mice	NULL
)	NULL
reveal	NULL
that	NULL
only	NULL
54.2	NULL
%	NULL
or	NULL
13	NULL
of	NULL
24	NULL
mice	NULL
survived	NULL
.	NULL

This	NULL
survival	NULL
difference	NULL
between	NULL
wild-type	NULL
and	NULL
transgenic	NULL
mice	NULL
is	NULL
significant	NULL
using	NULL
either	NULL
the	NULL
Wilcoxon	NULL
or	NULL
log	NULL
rank	NULL
statistical	NULL
tests	NULL
(	NULL
P	NULL
values	NULL
=	NULL
0.0043	NULL
)	NULL
.	NULL

The	NULL
lethality	NULL
was	NULL
not	NULL
due	NULL
to	NULL
acute	NULL
radiation	NULL
toxicity	NULL
,	NULL
since	NULL
no	NULL
deaths	NULL
occurred	NULL
until	NULL
day	NULL
7	NULL
following	NULL
irradiation	NULL
.	NULL

Induced	NULL
lethality	NULL
was	NULL
associated	NULL
with	NULL
the	NULL
duration	NULL
and	NULL
degree	NULL
of	NULL
leukopenia	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
and	NULL
granulocytopenia	NULL
.	NULL

Additional	NULL
studies	NULL
were	NULL
conducted	NULL
to	NULL
examine	NULL
whether	NULL
RA	NULL
treatment	NULL
of	NULL
irradiated	NULL
PML/RARa	NULL
transgenic	NULL
mice	NULL
limits	NULL
induced	NULL
leukopenia	NULL
or	NULL
granulocytopenia	NULL
.	NULL

Vehicle	NULL
(	NULL
DMSO	NULL
)	NULL
-treated	NULL
PML/RARa	NULL
transgenic	NULL
mice	NULL
served	NULL
as	NULL
controls	NULL
.	NULL

The	NULL
results	NULL
of	NULL
a	NULL
representative	NULL
experiment	NULL
appear	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Since	NULL
DMSO	NULL
protects	NULL
against	NULL
radiation-induced	NULL
damage	NULL
in	NULL
vivo	NULL
(	NULL
31	NULL
)	NULL
,	NULL
the	NULL
end-point	NULL
for	NULL
this	NULL
study	NULL
was	NULL
not	NULL
survival	NULL
but	NULL
duration	NULL
and	NULL
extent	NULL
of	NULL
radiation-induced	NULL
granulocytopenia	NULL
.	NULL

As	NULL
compared	NULL
with	NULL
controls	NULL
,	NULL
PML	NULL
/RARa	NULL
transgenic	NULL
mice	NULL
treated	NULL
with	NULL
RA	NULL
exhibit	NULL
more	NULL
rapid	NULL
granulocyte	NULL
recovery	NULL
.	NULL

This	NULL
reaches	NULL
statistical	NULL
significance	NULL
by	NULL
day	NULL
8	NULL
using	NULL
the	NULL
two-tailed	NULL
Student	NULL
's	NULL
¢	NULL
test	NULL
~	NULL
(	NULL
P	NULL
value	NULL
<	NULL
0.05	NULL
;	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

By	NULL
day	NULL
14	NULL
postirradiation	NULL
,	NULL
granulocyte	NULL
Medical	NULL
Sciences	NULL
:	NULL
Early	NULL
et	NULL
al	NULL
.	NULL

A	NULL
Wild-type	NULL
120	NULL
MTransgene	NULL
€	NULL
100	NULL
£5	NULL
80	NULL
g	NULL
=	NULL
os	NULL
eo	NULL
O	NULL
o	NULL
=z	NULL
40	NULL
®	NULL
5	NULL
&	NULL
20	NULL
O	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
7903	NULL
B	NULL
100	NULL
.-~	NULL
--	NULL
———m	NULL
90	NULL
A-80	NULL
Lh-	NULL
Ta	NULL
.	NULL

2	NULL
70	NULL
Pas	NULL
>	NULL
60	NULL
-	NULL
L	NULL
lnlatninteln	NULL
``	NULL
g	NULL
50	NULL
,	NULL
I	NULL
mme	NULL
mt	NULL
moe	NULL
me	NULL
i	NULL
&	NULL
w	NULL
40	NULL
.	NULL

sonicc	NULL
#	NULL
30	NULL
{	NULL
-=-	NULL
wild	NULL
type	NULL
20	NULL
|	NULL
|	NULL
-**-	NULL
transgene	NULL
16	NULL
10	NULL
I	NULL
0	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
1	NULL
0	NULL
5	NULL
10	NULL
15	NULL
20	NULL
25	NULL
DAYS	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

(	NULL
4	NULL
)	NULL
The	NULL
percent	NULL
WBC	NULL
counts	NULL
(	NULL
PML	NULL
/RARa	NULL
transgenic	NULL
versus	NULL
wild-type	NULL
mice	NULL
)	NULL
before	NULL
and	NULL
at	NULL
indicated	NULL
time	NULL
points	NULL
after	NULL
a	NULL
single	NULL
dose	NULL
of	NULL
600	NULL
rad/mouse	NULL
.	NULL

This	NULL
figure	NULL
demonstrates	NULL
the	NULL
transgenic	NULL
mice	NULL
had	NULL
a	NULL
more	NULL
rapid	NULL
and	NULL
sustained	NULL
suppression	NULL
of	NULL
WBC	NULL
counts	NULL
than	NULL
controls	NULL
.	NULL

The	NULL
bars	NULL
depict	NULL
the	NULL
standard	NULL
error	NULL
of	NULL
the	NULL
mean	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
survival	NULL
curve	NULL
of	NULL
these	NULL
irradiated	NULL
wild-type	NULL
versus	NULL
PML	NULL
/RARa	NULL
«	NULL
transgenic	NULL
mice	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
nearly	NULL
all	NULL
wild-type	NULL
mice	NULL
(	NULL
94.4	NULL
%	NULL
)	NULL
survived	NULL
,	NULL
while	NULL
only	NULL
(	NULL
54.2	NULL
%	NULL
)	NULL
PML/RARa	NULL
transgenic	NULL
mice	NULL
survived	NULL
irradiation	NULL
.	NULL

This	NULL
difference	NULL
is	NULL
significant	NULL
(	NULL
P	NULL
values	NULL
=	NULL
0.0043	NULL
)	NULL
as	NULL
discussed	NULL
in	NULL
Results	NULL
.	NULL

counts	NULL
were	NULL
3-fold	NULL
higher	NULL
in	NULL
RA-treated	NULL
mice	NULL
as	NULL
compared	NULL
with	NULL
controls	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Results	NULL
were	NULL
similar	NULL
in	NULL
a	NULL
duplicate	NULL
independent	NULL
experiment	NULL
.	NULL

Thus	NULL
,	NULL
RA	NULL
treatment	NULL
of	NULL
PML/RARa	NULL
transgenic	NULL
mice	NULL
antagonizes	NULL
radiation	NULL
induced	NULL
granulocytopenia	NULL
.	NULL

DISCUSSION	NULL
This	NULL
study	NULL
reports	NULL
that	NULL
CD11b	NULL
driven	NULL
PML	NULL
/RARa	NULL
transgenic	NULL
expression	NULL
in	NULL
mice	NULL
impairs	NULL
myelopoiesis	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vifro	NULL
.	NULL

CD11b	NULL
is	NULL
the	NULL
a	NULL
chain	NULL
of	NULL
the	NULL
Mac-1	NULL
integrin	NULL
and	NULL
is	NULL
preferentially	NULL
100	NULL
10	NULL
%	NULL
Basal	NULL
Granulocyte	NULL
Count	NULL
®-	NULL
@	NULL
Transgene	NULL
(	NULL
Vehicle	NULL
)	NULL
O	NULL
Transgene	NULL
(	NULL
RA	NULL
)	NULL
Days	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

The	NULL
recovery	NULL
of	NULL
granulocyte	NULL
counts	NULL
of	NULL
PML	NULL
/RARa	NULL
mice	NULL
after	NULL
a	NULL
single	NULL
dose	NULL
of	NULL
600	NULL
rad/mouse	NULL
and	NULL
treatment	NULL
with	NULL
DMSO	NULL
(	NULL
vehicle	NULL
)	NULL
or	NULL
RA	NULL
.	NULL

As	NULL
compared	NULL
with	NULL
controls	NULL
,	NULL
this	NULL
study	NULL
demonstrates	NULL
that	NULL
RA	NULL
treatment	NULL
enhances	NULL
the	NULL
granulocyte	NULL
recovery	NULL
following	NULL
radiation	NULL
treatment	NULL
of	NULL
these	NULL
PML	NULL
transgenic	NULL
mice	NULL
.	NULL

The	NULL
more	NULL
rapid	NULL
granulocyte	NULL
recovery	NULL
at	NULL
day	NULL
8	NULL
is	NULL
statistically	NULL
significant	NULL
(	NULL
depicted	NULL
by	NULL
the	NULL
*	NULL
)	NULL
using	NULL
the	NULL
two-tailed	NULL
Student	NULL
's	NULL
£	NULL
test	NULL
(	NULL
P	NULL
=.05	NULL
)	NULL
.	NULL

Similar	NULL
findings	NULL
were	NULL
observed	NULL
in	NULL
a	NULL
second	NULL
independent	NULL
experiment	NULL
.	NULL

The	NULL
y	NULL
axis	NULL
depicts	NULL
a	NULL
logarithmic	NULL
scale	NULL
of	NULL
%	NULL
basal	NULL
granulocyte	NULL
count	NULL
,	NULL
and	NULL
the	NULL
x	NULL
axis	NULL
represents	NULL
the	NULL
time	NULL
in	NULL
days	NULL
.	NULL

The	NULL
interrupted	NULL
line	NULL
indicates	NULL
that	NULL
granulocyte	NULL
counts	NULL
were	NULL
not	NULL
measured	NULL
until	NULL
day	NULL
5.	NULL
expressed	NULL
in	NULL
myeloid	NULL
cells	NULL
(	NULL
27-30	NULL
)	NULL
.	NULL

The	NULL
CD11b	NULL
promoter	NULL
directs	NULL
cell	NULL
type-specific	NULL
expression	NULL
in	NULL
myelomonocytic	NULL
cells	NULL
,	NULL
which	NULL
are	NULL
known	NULL
to	NULL
be	NULL
sensitive	NULL
to	NULL
GM-CSF	NULL
(	NULL
27-30	NULL
)	NULL
.	NULL

Since	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
the	NULL
CD11b	NULL
promoter	NULL
is	NULL
not	NULL
active	NULL
in	NULL
myeloid	NULL
progenitors	NULL
(	NULL
27-30	NULL
)	NULL
,	NULL
it	NULL
is	NULL
expected	NULL
that	NULL
changes	NULL
in	NULL
HPP-CFC	NULL
and	NULL
LPP-CFC	NULL
progenitors	NULL
would	NULL
not	NULL
be	NULL
found	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
PML/RARa	NULL
transgenic	NULL
expression	NULL
causes	NULL
marked	NULL
suppression	NULL
of	NULL
CFU-GMs	NULL
in	NULL
peripheral	NULL
blood	NULL
clonal	NULL
growth	NULL
assays	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

24	NULL
.	NULL

The	NULL
in	NULL
vitro	NULL
suppression	NULL
of	NULL
CFU-GMs	NULL
is	NULL
not	NULL
overcome	NULL
when	NULL
PML	NULL
myeloid	NULL
cells	NULL
are	NULL
cultured	NULL
with	NULL
GM-CSF	NULL
and	NULL
KL	NULL
.	NULL

Those	NULL
colonies	NULL
forming	NULL
from	NULL
control	NULL
and	NULL
transgenic	NULL
peripheral	NULL
blood	NULL
were	NULL
of	NULL
a	NULL
smaller	NULL
size	NULL
(	NULL
50-200	NULL
cells/colony	NULL
)	NULL
than	NULL
CFU-GMs	NULL
in	NULL
bone	NULL
marrow	NULL
(	NULL
50-10,000	NULL
cells/colony	NULL
)	NULL
and	NULL
probably	NULL
represent	NULL
a	NULL
more	NULL
differentiated	NULL
progenitor	NULL
population	NULL
.	NULL

Notably	NULL
,	NULL
a	NULL
minimal	NULL
suppression	NULL
of	NULL
CFU-GMs	NULL
is	NULL
present	NULL
in	NULL
clonal	NULL
growth	NULL
assays	NULL
performed	NULL
with	NULL
bone	NULL
marrow	NULL
derived	NULL
from	NULL
the	NULL
PML/RARa	NULL
transgenic	NULL
line	NULL
.	NULL

This	NULL
difference	NULL
between	NULL
clonal	NULL
growth	NULL
results	NULL
from	NULL
peripheral	NULL
blood	NULL
versus	NULL
bone	NULL
marrow	NULL
cells	NULL
could	NULL
reflect	NULL
the	NULL
reduced	NULL
capacity	NULL
of	NULL
the	NULL
PML	NULL
/RARa	NULL
transgene	NULL
to	NULL
mobilize	NULL
progenitor	NULL
myeloid	NULL
cells	NULL
to	NULL
peripheral	NULL
or	NULL
extramedullary	NULL
sites	NULL
.	NULL

This	NULL
may	NULL
partly	NULL
account	NULL
for	NULL
the	NULL
enhanced	NULL
sensitivity	NULL
of	NULL
these	NULL
transgenic	NULL
mice	NULL
to	NULL
irradiation	NULL
.	NULL

This	NULL
finding	NULL
is	NULL
not	NULL
without	NULL
precedence	NULL
.	NULL

For	NULL
example	NULL
,	NULL
mice	NULL
bearing	NULL
mutant	NULL
genes	NULL
at	NULL
the	NULL
W	NULL
or	NULL
Steel	NULL
loci	NULL
have	NULL
modest	NULL
changes	NULL
observed	NULL
in	NULL
bone	NULL
marrow	NULL
clonal	NULL
growth	NULL
assays	NULL
,	NULL
yet	NULL
these	NULL
mice	NULL
also	NULL
have	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
wild-type	NULL
mice	NULL
,	NULL
enhanced	NULL
radiation	NULL
sensitivity	NULL
(	NULL
32-34	NULL
)	NULL
.	NULL

Although	NULL
almost	NULL
all	NULL
control	NULL
mice	NULL
survived	NULL
sublethal	NULL
irradiation	NULL
,	NULL
nearly	NULL
50	NULL
%	NULL
of	NULL
PML/RARa	NULL
mice	NULL
succumbed	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

This	NULL
lethality	NULL
was	NULL
associated	NULL
with	NULL
a	NULL
greater	NULL
degree	NULL
of	NULL
granulocytopenia	NULL
and	NULL
leukopenia	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
in	NULL
PML/RARa	NULL
versus	NULL
control	NULL
mice	NULL
.	NULL

Other	NULL
cellular	NULL
defects	NULL
in	NULL
addition	NULL
to	NULL
granulocytopenia	NULL
and	NULL
leukopenia	NULL
could	NULL
contribute	NULL
to	NULL
this	NULL
increased	NULL
lethality	NULL
.	NULL

This	NULL
includes	NULL
altered	NULL
granulocytic	NULL
functions	NULL
(	NULL
migra-tion	NULL
and	NULL
phagocytosis	NULL
)	NULL
and	NULL
altered	NULL
stromal-bone	NULL
marrow	NULL
interactions	NULL
or	NULL
splenic	NULL
extramedullary	NULL
hematopoiesis	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Although	NULL
multiple	NULL
factors	NULL
may	NULL
contribute	NULL
to	NULL
this	NULL
lethality	NULL
,	NULL
it	NULL
is	NULL
apparent	NULL
that	NULL
RA	NULL
treatment	NULL
antagonizes	NULL
some	NULL
inhibitory	NULL
effects	NULL
of	NULL
PML/RARa	NULL
on	NULL
myelopoiesis	NULL
.	NULL

RA	NULL
treatment	NULL
of	NULL
these	NULL
transgenic	NULL
mice	NULL
enhances	NULL
granulocyte	NULL
recovery	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Finding	NULL
an	NULL
inhibitory	NULL
effect	NULL
of	NULL
PML	NULL
expression	NULL
on	NULL
myelopoiesis	NULL
is	NULL
not	NULL
unexpected	NULL
.	NULL

Prior	NULL
work	NULL
reveals	NULL
that	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
ligand	NULL
,	NULL
PML/RARa	NULL
functions	NULL
as	NULL
an	NULL
inhibitory	NULL
transcription	NULL
factor	NULL
with	NULL
putative	NULL
dominant	NULL
negative	NULL
functions	NULL
(	NULL
4	NULL
,	NULL
5	NULL
,	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

In	NULL
certain	NULL
myeloid	NULL
leukemic	NULL
cells	NULL
,	NULL
engineered	NULL
PML/RARa	NULL
overexpression	NULL
inhibits	NULL
induced	NULL
differentiation	NULL
(	NULL
11	NULL
,	NULL
15	NULL
)	NULL
.	NULL

In	NULL
defined	NULL
cell	NULL
contexts	NULL
,	NULL
PML/RARa	NULL
expression	NULL
exerts	NULL
an	NULL
inhibitory	NULL
effect	NULL
on	NULL
the	NULL
transactivation	NULL
of	NULL
reporters	NULL
containing	NULL
retinoic	NULL
acid	NULL
response	NULL
elements	NULL
(	NULL
4	NULL
,	NULL
5	NULL
,	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
7904	NULL
Medical	NULL
Sciences	NULL
:	NULL
Early	NULL
et	NULL
al	NULL
.	NULL

PML	NULL
/RARa	NULL
expression	NULL
leads	NULL
to	NULL
aberrant	NULL
nuclear	NULL
localization	NULL
of	NULL
PML	NULL
in	NULL
APL	NULL
cells	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
,	NULL
and	NULL
RA	NULL
restores	NULL
a	NULL
normal	NULL
nuclear	NULL
localization	NULL
pattern	NULL
.	NULL

Overexpression	NULL
of	NULL
either	NULL
PML	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
or	NULL
RARa	NULL
(	NULL
17	NULL
)	NULL
in	NULL
NB4	NULL
cells	NULL
leads	NULL
to	NULL
growth	NULL
suppression	NULL
either	NULL
through	NULL
a	NULL
direct	NULL
growth	NULL
suppressive	NULL
effect	NULL
of	NULL
PML	NULL
or	NULL
RARa	NULL
or	NULL
indirectly	NULL
through	NULL
an	NULL
antagonism	NULL
of	NULL
the	NULL
inhibitory	NULL
PML/RARa	NULL
effects	NULL
in	NULL
APL	NULL
cells	NULL
(	NULL
17	NULL
)	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
myelopoiesis	NULL
reported	NULL
here	NULL
has	NULL
clinical	NULL
implications	NULL
.	NULL

That	NULL
RA	NULL
treatment	NULL
of	NULL
irradiated	NULL
mice	NULL
antagonizes	NULL
the	NULL
granulocytopenia	NULL
found	NULL
in	NULL
PML/RARa	NULL
transgenic	NULL
mice	NULL
is	NULL
reminiscent	NULL
of	NULL
the	NULL
clinical	NULL
retinoid	NULL
response	NULL
of	NULL
APL	NULL
patients	NULL
.	NULL

RA	NULL
treatment	NULL
overcomes	NULL
the	NULL
clinical	NULL
maturation	NULL
block	NULL
found	NULL
in	NULL
leukemic	NULL
promyelocytes	NULL
,	NULL
presumably	NULL
due	NULL
to	NULL
antagonism	NULL
of	NULL
the	NULL
actions	NULL
of	NULL
PML	NULL
/RARa	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

Since	NULL
DMSO	NULL
protects	NULL
against	NULL
radiation	NULL
damage	NULL
(	NULL
31	NULL
)	NULL
,	NULL
this	NULL
likely	NULL
accounts	NULL
for	NULL
the	NULL
more	NULL
limited	NULL
granulocytopenia	NULL
found	NULL
in	NULL
vehicle-treated	NULL
and	NULL
irradiated	NULL
PML	NULL
/RARa	NULL
mice	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
than	NULL
in	NULL
transgenic	NULL
or	NULL
control	NULL
mice	NULL
not	NULL
treated	NULL
with	NULL
DMSO	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
these	NULL
PML	NULL
/RARa	NULL
transgenic	NULL
mice	NULL
do	NULL
not	NULL
develop	NULL
leukemia	NULL
or	NULL
obvious	NULL
hematopathology	NULL
,	NULL
despite	NULL
more	NULL
than	NULL
2	NULL
years	NULL
of	NULL
follow-up	NULL
.	NULL

Several	NULL
factors	NULL
could	NULL
contribute	NULL
to	NULL
these	NULL
findings	NULL
.	NULL

The	NULL
low	NULL
levels	NULL
of	NULL
PML/RARa	NULL
expressed	NULL
in	NULL
bone	NULL
marrow	NULL
cells	NULL
from	NULL
these	NULL
transgenic	NULL
mice	NULL
suggest	NULL
that	NULL
an	NULL
optimal	NULL
PML	NULL
gene	NULL
dosage	NULL
is	NULL
required	NULL
to	NULL
fully	NULL
transform	NULL
myeloid	NULL
cells	NULL
.	NULL

Appropriate	NULL
timing	NULL
of	NULL
PML/RARa	NULL
«	NULL
expression	NULL
in	NULL
early	NULL
myeloid	NULL
cells	NULL
might	NULL
play	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
transformation	NULL
.	NULL

Perhaps	NULL
a	NULL
myeloid-specific	NULL
promoter	NULL
active	NULL
in	NULL
even	NULL
earlier	NULL
myeloid	NULL
cells	NULL
than	NULL
the	NULL
CD11b	NULL
promoter	NULL
used	NULL
to	NULL
engineer	NULL
this	NULL
transgenic	NULL
line	NULL
will	NULL
yield	NULL
higher	NULL
levels	NULL
of	NULL
PML	NULL
/	NULL
RARa	NULL
expression	NULL
in	NULL
these	NULL
progenitors	NULL
.	NULL

Alternatively	NULL
,	NULL
a	NULL
second	NULL
oncogenic	NULL
event	NULL
such	NULL
as	NULL
ras	NULL
or	NULL
p53	NULL
activation	NULL
may	NULL
be	NULL
required	NULL
to	NULL
develop	NULL
leukemia	NULL
(	NULL
36	NULL
,	NULL
37	NULL
)	NULL
.	NULL

This	NULL
PML	NULL
/R	NULL
AR	NULL
a	NULL
transgenic	NULL
line	NULL
may	NULL
prove	NULL
useful	NULL
to	NULL
identify	NULL
second	NULL
oncogenic	NULL
events	NULL
contributing	NULL
to	NULL
APL	NULL
development	NULL
.	NULL

Since	NULL
RA	NULL
treatment	NULL
of	NULL
this	NULL
irradiated	NULL
PML	NULL
/RARa	NULL
line	NULL
antagonizes	NULL
some	NULL
of	NULL
the	NULL
inhibitory	NULL
PML/RARa	NULL
effects	NULL
,	NULL
this	NULL
transgene	NULL
might	NULL
predict	NULL
useful	NULL
therapeutic	NULL
properties	NULL
of	NULL
RA	NULL
or	NULL
retinoid	NULL
analogs	NULL
before	NULL
use	NULL
in	NULL
APL	NULL
clinical	NULL
trials	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
these	NULL
studies	NULL
provide	NULL
the	NULL
first	NULL
direct	NULL
evidence	NULL
that	NULL
expression	NULL
of	NULL
PML/RARa	NULL
in	NULL
mice	NULL
can	NULL
trigger	NULL
abnormal	NULL
myelopoiesis	NULL
and	NULL
increased	NULL
radiation	NULL
sensitivity	NULL
.	NULL

RA	NULL
therapy	NULL
reverses	NULL
at	NULL
least	NULL
some	NULL
of	NULL
these	NULL
findings	NULL
,	NULL
suggesting	NULL
that	NULL
PML	NULL
/	NULL
RARa	NULL
mice	NULL
provide	NULL
a	NULL
useful	NULL
model	NULL
to	NULL
further	NULL
understand	NULL
the	NULL
basis	NULL
of	NULL
oncogenic	NULL
transformation	NULL
and	NULL
treatment	NULL
of	NULL
APL	NULL
patients	NULL
.	NULL

We	NULL
thank	NULL
Janet	NULL
Allopenna	NULL
and	NULL
Harry	NULL
Satterwhite	NULL
for	NULL
expert	NULL
technical	NULL
assistance	NULL
.	NULL

We	NULL
thank	NULL
Yue	NULL
Tao	NULL
,	NULL
Department	NULL
of	NULL
Biostatistics	NULL
,	NULL
Memorial	NULL
Sloan-Kettering	NULL
Cancer	NULL
Center	NULL
,	NULL
for	NULL
helpful	NULL
consultations	NULL
;	NULL
Dr.	NULL
M.	NULL
Lanotte	NULL
,	NULL
INSERM	NULL
,	NULL
France	NULL
for	NULL
the	NULL
gift	NULL
of	NULL
the	NULL
NB4	NULL
cell	NULL
line	NULL
;	NULL
and	NULL
Dr.	NULL
D.	NULL
Tenen	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
for	NULL
the	NULL
gift	NULL
of	NULL
the	NULL
CD11b	NULL
promoter	NULL
.	NULL

R.M.E	NULL
.	NULL

is	NULL
an	NULL
Investigator	NULL
of	NULL
the	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
for	NULL
Biological	NULL
Studies	NULL
.	NULL

These	NULL
studies	NULL
were	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
NIH	NULL
)	NULL
Grant	NULL
RO1-62275-02	NULL
to	NULL
E.D	NULL
.	NULL

,	NULL
the	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
for	NULL
Biological	NULL
Studies	NULL
,	NULL
and	NULL
NIH	NULL
Program	NULL
Project	NULL
CASS5418	NULL
to	NULL
R.M.E	NULL
.	NULL

K.N-B	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
NIH	NULL
National	NULL
Research	NULL
Service	NULL
Award	NULL
1F32CA61646-01A1	NULL
.	NULL

1	NULL
.	NULL

Borrow	NULL
,	NULL
J.	NULL
,	NULL
Goddard	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Sheer	NULL
,	NULL
D.	NULL
&	NULL
Solomon	NULL
,	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
Science	NULL
249	NULL
,	NULL
1577-1580	NULL
.	NULL

2	NULL
.	NULL

-	NULL
de	NULL
The	NULL
,	NULL
H.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Lanotte	NULL
,	NULL
M.	NULL
,	NULL
Degos	NULL
,	NULL
L.	NULL
&	NULL
Dejean	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
347	NULL
,	NULL
558-561	NULL
,	NULL
3	NULL
.	NULL

Longo	NULL
,	NULL
L.	NULL
,	NULL
Pardolfi	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Biondi	NULL
,	NULL
A.	NULL
,	NULL
Rambaldi	NULL
,	NULL
A.	NULL
,	NULL
Mencarelli	NULL
,	NULL
A.	NULL
,	NULL
LoCoco	NULL
,	NULL
F.	NULL
,	NULL
Diverio	NULL
,	NULL
D.	NULL
,	NULL
Pegoraro	NULL
,	NULL
L.	NULL
,	NULL
Avanzi	NULL
,	NULL
G.	NULL
,	NULL
Tabilio	NULL
,	NULL
A.	NULL
,	NULL
Zangrilli	NULL
,	NULL
D.	NULL
,	NULL
Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Donti	NULL
,	NULL
E.	NULL
,	NULL
Grignani	NULL
,	NULL
F.	NULL
&	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172	NULL
,	NULL
1571-1575	NULL
.	NULL

4	NULL
.	NULL

-	NULL
Kakizuka	NULL
,	NULL
A.	NULL
,	NULL
Miller	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Jr.	NULL
,	NULL
Umesono	NULL
,	NULL
K.	NULL
,	NULL
Wartell	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
,	NULL
Frankel	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Murty	NULL
,	NULL
V.	NULL
V.	NULL
V.	NULL
S.	NULL
,	NULL
Driitrovsky	NULL
,	NULL
E.	NULL
&	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
66	NULL
,	NULL
663-674	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
de	NULL
The	NULL
,	NULL
H.	NULL
,	NULL
Lavau	NULL
,	NULL
C.	NULL
,	NULL
Marcio	NULL
,	NULL
A.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Degos	NULL
,	NULL
L	NULL
:	NULL
&	NULL
Dejean	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Cell	NULL
66	NULL
,	NULL
675-684	NULL
.	NULL

Miller	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Jr.	NULL
,	NULL
Kakizuka	NULL
,	NULL
A.	NULL
,	NULL
Frankel	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Warrell	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
,	NULL
DeBlasio	NULL
,	NULL
A.	NULL
,	NULL
Levine	NULL
,	NULL
K.	NULL
,	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
&	NULL
Dmitrovsky	NULL
,	NULL
E.	NULL
(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
,	NULL
2694-2698	NULL
.	NULL

Chen	NULL
,	NULL
Z.	NULL
,	NULL
Brand	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Chen	NULL
,	NULL
A.	NULL
,	NULL
Chen	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Tong	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Wang	NULL
,	NULL
Z.	NULL
Y.	NULL
,	NULL
Waxman	NULL
,	NULL
S.	NULL
&	NULL
Zelent	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

12	NULL
,	NULL
1161-1168	NULL
.	NULL

Huang	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Ye	NULL
,	NULL
Y.	NULL
C.	NULL
,	NULL
Chen	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Chai	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Lu	NULL
,	NULL
J.	NULL
X.	NULL
,	NULL
Zhoa	NULL
,	NULL
L.	NULL
,	NULL
Gu	NULL
,	NULL
L.	NULL
J	NULL
.	NULL

&	NULL
Wang	NULL
,	NULL
Z.	NULL
Y	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Blood	NULL
72	NULL
,	NULL
567-572	NULL
.	NULL

Castaigne	NULL
,	NULL
S.	NULL
,	NULL
Chomienne	NULL
,	NULL
C.	NULL
,	NULL
Daniel	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Berger	NULL
,	NULL
R.	NULL
,	NULL
Fenaux	NULL
,	NULL
P.	NULL
&	NULL
Degos	NULL
,	NULL
L.	NULL
(	NULL
1990	NULL
)	NULL
Blood	NULL
76	NULL
,	NULL
1704-1709	NULL
.	NULL

Wartell	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
Jr.	NULL
,	NULL
Frankel	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Miller	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Jr.	NULL
,	NULL
Scheinberg	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Itri	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Hittelman	NULL
,	NULL
W.	NULL
N.	NULL
,	NULL
Vyas	NULL
,	NULL
R.	NULL
,	NULL
Andreeff	NULL
,	NULL
M.	NULL
,	NULL
Tafuri	NULL
,	NULL
A.	NULL
,	NULL
Jakubowski	NULL
,	NULL
A.	NULL
,	NULL
Gabrilove	NULL
,	NULL
J.	NULL
,	NULL
Gordon	NULL
,	NULL
M.S	NULL
.	NULL

&	NULL
Dmitrovsky	NULL
,	NULL
E.	NULL
(	NULL
1991	NULL
)	NULL
N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

324	NULL
,	NULL
1385-1393	NULL
.	NULL

Rousselot	NULL
,	NULL
P.	NULL
,	NULL
Hardas	NULL
,	NULL
B.	NULL
,	NULL
Patel	NULL
,	NULL
A.	NULL
,	NULL
Guidez	NULL
,	NULL
F.	NULL
,	NULL
Gaken	NULL
,	NULL
J.	NULL
,	NULL
Castaigne	NULL
,	NULL
S.	NULL
,	NULL
Dejean	NULL
,	NULL
A.	NULL
,	NULL
de	NULL
The	NULL
,	NULL
H.	NULL
,	NULL
Degos	NULL
,	NULL
L.	NULL
,	NULL
Farzaneh	NULL
,	NULL
F.	NULL
&	NULL
Chomienne	NULL
,	NULL
C.	NULL
(	NULL
1994	NULL
)	NULL
Oncogene	NULL
9	NULL
,	NULL
545-551	NULL
.	NULL

Kastner	NULL
,	NULL
P.	NULL
,	NULL
Perez	NULL
,	NULL
A.	NULL
,	NULL
Lutz	NULL
,	NULL
Y.	NULL
,	NULL
Rochette-Egly	NULL
,	NULL
C.	NULL
,	NULL
Gaub	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Durand	NULL
,	NULL
B.	NULL
,	NULL
Lanotte	NULL
,	NULL
M.	NULL
,	NULL
Berger	NULL
,	NULL
R.	NULL
&	NULL
Chambon	NULL
P.	NULL
(	NULL
1992	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

11	NULL
,	NULL
629-642	NULL
.	NULL

Weis	NULL
,	NULL
K.	NULL
,	NULL
Rambaud	NULL
,	NULL
S.	NULL
,	NULL
Lavau	NULL
,	NULL
C.	NULL
,	NULL
Jansen	NULL
,	NULL
J.	NULL
,	NULL
Carvalho	NULL
,	NULL
T.	NULL
,	NULL
Carmo-Fonseca	NULL
M.	NULL
,	NULL
Lamond	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Dejean	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cell	NULL
76	NULL
,	NULL
345-356	NULL
.	NULL

Dyck	NULL
,	NULL
J.	NULL
,	NULL
Maul	NULL
,	NULL
G.	NULL
,	NULL
Miller	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Jr.	NULL
,	NULL
Chen	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Kakizuka	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
76	NULL
,	NULL
333-343	NULL
.	NULL

Grignani	NULL
,	NULL
F.	NULL
,	NULL
Ferrucei	NULL
,	NULL
P.	NULL
F.	NULL
,	NULL
Testa	NULL
,	NULL
U.	NULL
,	NULL
Talamo	NULL
,	NULL
G.	NULL
,	NULL
Fagioli	NULL
,	NULL
M.	NULL
,	NULL
Alcalay	NULL
,	NULL
M.	NULL
,	NULL
Mencarelli	NULL
,	NULL
A.	NULL
,	NULL
Grignani	NULL
,	NULL
F.	NULL
,	NULL
Peschle	NULL
,	NULL
C.	NULL
,	NULL
Nicoletti	NULL
,	NULL
I	NULL
.	NULL

&	NULL
Pelicci	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1993	NULL
)	NULL
Cell	NULL
74	NULL
,	NULL
423-431	NULL
.	NULL

Lanotte	NULL
,	NULL
M.	NULL
,	NULL
Martin-Thouvenin	NULL
,	NULL
V.	NULL
,	NULL
Najman	NULL
,	NULL
S.	NULL
,	NULL
Balerini	NULL
,	NULL
P.	NULL
,	NULL
Valensi	NULL
,	NULL
F.	NULL
&	NULL
Berger	NULL
,	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Blood	NULL
77	NULL
,	NULL
1080-1086	NULL
.	NULL

Ahn	NULL
,	NULL
M.-J	NULL
.	NULL

,	NULL
Nason-Burchenal	NULL
,	NULL
K.	NULL
,	NULL
Moasser	NULL
,	NULL
M.	NULL
M.	NULL
&	NULL
Dmitrovsky	NULL
,	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
Oncogene	NULL
10	NULL
,	NULL
2307-2314	NULL
.	NULL

Mu	NULL
,	NULL
Z.-M.	NULL
,	NULL
Chin	NULL
,	NULL
K.-V.	NULL
,	NULL
Liu	NULL
,	NULL
J.-H.	NULL
,	NULL
Lozano	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Chang	NULL
,	NULL
K-S.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
6858-6867	NULL
.	NULL

Tsai	NULL
,	NULL
S.	NULL
&	NULL
Collins	NULL
,	NULL
S.J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
,	NULL
7153-7157	NULL
.	NULL

Tsai	NULL
,	NULL
S.	NULL
,	NULL
Bartelmez	NULL
,	NULL
S.	NULL
,	NULL
Sitnicka	NULL
,	NULL
E.	NULL
&	NULL
Collins	NULL
,	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

8	NULL
,	NULL
2831-2841	NULL
.	NULL

Chirgwin	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Przybyla	NULL
,	NULL
A.	NULL
F.	NULL
,	NULL
MacDonald	NULL
,	NULL
R.J.	NULL
&	NULL
Rutter	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
Biochemistry	NULL
18	NULL
,	NULL
5294-5299	NULL
.	NULL

Southern	NULL
,	NULL
E.	NULL
M.	NULL
(	NULL
1975	NULL
)	NULL
J.	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

98	NULL
,	NULL
503-517	NULL
.	NULL

Heyman	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Borrelli	NULL
,	NULL
E.	NULL
,	NULL
Lesley	NULL
,	NULL
J.	NULL
,	NULL
Anderson	NULL
,	NULL
D.	NULL
,	NULL
Richman	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
Baird	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Hyman	NULL
,	NULL
R.	NULL
&	NULL
Evans	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86	NULL
,	NULL
2698-2702	NULL
.	NULL

Muench	NULL
,	NULL
M.	NULL
O.	NULL
,	NULL
Schneider	NULL
,	NULL
J.	NULL
G.	NULL
&	NULL
Moore	NULL
,	NULL
M.	NULL
A.	NULL
S.	NULL
(	NULL
1992	NULL
)	NULL
Exp	NULL
.	NULL

Hematol	NULL
.	NULL

20	NULL
,	NULL
339-349	NULL
.	NULL

Muench	NULL
,	NULL
M.	NULL
O.	NULL
,	NULL
Guy	NULL
,	NULL
Z	NULL
.	NULL

&	NULL
Moore	NULL
,	NULL
M.	NULL
A.	NULL
S.	NULL
(	NULL
1992	NULL
)	NULL
Cancer	NULL
Res	NULL
.	NULL

52	NULL
,	NULL
6576-6582	NULL
.	NULL

Muench	NULL
,	NULL
M.	NULL
O	NULL
.	NULL

&	NULL
Moore	NULL
,	NULL
M.	NULL
A.S.	NULL
(	NULL
1992	NULL
)	NULL
Exp	NULL
.	NULL

Hemat	NULL
.	NULL

20	NULL
,	NULL
611-618	NULL
.	NULL

Shelley	NULL
,	NULL
C.	NULL
S.	NULL
&	NULL
Arnout	NULL
,	NULL
A	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
USA	NULL
88	NULL
,	NULL
10525-10529	NULL
.	NULL

Hickstein	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
Baker	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Gollahon	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

&	NULL
Back	NULL
,	NULL
A.	NULL
L.	NULL
(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
,	NULL
2105-2109	NULL
.	NULL

Dziennis	NULL
,	NULL
S.	NULL
,	NULL
Van	NULL
Etten	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Pahl	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Morris	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Roth-stein	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
Blosch	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Perlmutter	NULL
,	NULL
R.	NULL
M.	NULL
&	NULL
Tenen	NULL
,	NULL
D.	NULL
G.	NULL
(	NULL
1995	NULL
)	NULL
Blood	NULL
85	NULL
,	NULL
319-329	NULL
.	NULL

Pahl	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Rosmarin	NULL
,	NULL
A.	NULL
G.	NULL
&	NULL
Tenen	NULL
,	NULL
D.	NULL
G.	NULL
(	NULL
1992	NULL
)	NULL
Blood	NULL
79	NULL
,	NULL
865-870	NULL
.	NULL

Ueda	NULL
,	NULL
T.	NULL
,	NULL
Toyoshima	NULL
,	NULL
Y.	NULL
,	NULL
Kushihashi	NULL
,	NULL
T.	NULL
,	NULL
Hishida	NULL
,	NULL
T.	NULL
&	NULL
Yasuhara	NULL
,	NULL
H.	NULL
(	NULL
1993	NULL
)	NULL
J	NULL
Toxicol	NULL
.	NULL

Sci	NULL
.	NULL

18	NULL
,	NULL
239-244	NULL
.	NULL

Harrison	NULL
,	NULL
D.	NULL
E.	NULL
(	NULL
1979	NULL
)	NULL
Clin	NULL
Haematol	NULL
.	NULL

8	NULL
,	NULL
239-262	NULL
.	NULL

Bernstein	NULL
,	NULL
S.	NULL
E.	NULL
&	NULL
Russell	NULL
,	NULL
E.	NULL
S.	NULL
(	NULL
1959	NULL
)	NULL
Proc	NULL
.	NULL

Soc	NULL
.	NULL

Exp	NULL
.	NULL

Biol	NULL
.	NULL

Med	NULL
.	NULL

101	NULL
,	NULL
769-773	NULL
.	NULL

McCulloch	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Siminovitch	NULL
,	NULL
L.	NULL
,	NULL
Till	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Russel	NULL
,	NULL
E.	NULL
S.	NULL
&	NULL
Bernstein	NULL
,	NULL
S.	NULL
E.	NULL
(	NULL
1965	NULL
)	NULL
Blood	NULL
26	NULL
,	NULL
399-410	NULL
.	NULL

Slordal	NULL
,	NULL
L.	NULL
,	NULL
Warren	NULL
,	NULL
D.	NULL
J	NULL
.	NULL

&	NULL
Moore	NULL
,	NULL
M.	NULL
A.	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

142	NULL
,	NULL
833-835	NULL
.	NULL

Bos	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Toksoz	NULL
,	NULL
D.	NULL
,	NULL
Marshall	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Verlaan-de	NULL
Vries	NULL
,	NULL
M.	NULL
,	NULL
Veeneman	NULL
,	NULL
G.	NULL
H.	NULL
,	NULL
van	NULL
der	NULL
Eb	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
van	NULL
Boom	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Janssen	NULL
,	NULL
J.	NULL
W.	NULL
G.	NULL
&	NULL
Steenvoorden	NULL
,	NULL
A.	NULL
C.	NULL
M.	NULL
(	NULL
1985	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
315	NULL
,	NULL
726-730	NULL
.	NULL

Slingerland	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Minden	NULL
,	NULL
M.	NULL
D.	NULL
&	NULL
Benchimol	NULL
,	NULL
S.	NULL
(	NULL
1991	NULL
)	NULL
Blood	NULL
77	NULL
,	NULL
1500-1507	NULL
.	NULL

